Indivior (NASDAQ:INDV) Posts Earnings Results, Beats Expectations By $0.17 EPS

Indivior (NASDAQ:INDV) issued its quarterly earnings data on Thursday. The company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.65 by $0.17, Zacks reports. Indivior had a negative return on equity of 90.79% and a net margin of 9.83%.

Here are the key takeaways from Indivior’s conference call:

• Indivior reported strong 2025 results with SUBLOCADE net revenue of $856M (up 13%), total net revenue of $1.24B (up 4%), and record adjusted EBITDA of $428M (up 20%) with notable margin improvement.
• Management gave 2026 guidance calling for accelerated momentum — mid-teens U.S. SUBLOCADE dispense growth, SUBLOCADE net revenue of $905M–$945M (~8% at midpoint), adjusted EBITDA of $535M–$575M (≈30% growth) and ~ $300M operating cash flow.
• The company completed organizational simplification and set a 2026 non-GAAP operating expense target of ≤$450M after taking $120M of restructuring charges in 2025 (≈$28M cash cost), which should improve leverage but involved upfront costs.
• Indivior strengthened its financial flexibility by paying the $295M DOJ obligation (eliminating a legacy liability), exiting 2025 with net leverage below 1x, and announcing a new $400M opportunistic share repurchase program while prioritizing debt management and commercial-stage M&A.
• Management warned of headwinds in 2026 that pressure total revenue at the midpoint — expected U.S. SUBOXONE Film pricing pressure, lower rest-of-world revenue after optimization, gross-to-net movements, and continued PERSERIS runoff.

Indivior Price Performance

INDV stock traded up $0.08 during midday trading on Thursday, hitting $33.71. The company’s stock had a trading volume of 2,927,012 shares, compared to its average volume of 1,826,706. The company’s fifty day moving average price is $34.64 and its 200 day moving average price is $29.89. Indivior has a twelve month low of $8.34 and a twelve month high of $38.00. The stock has a market capitalization of $4.21 billion, a P/E ratio of 36.64 and a beta of 0.80.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on INDV. HC Wainwright raised their price target on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Zacks Research cut Indivior from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 13th. Craig Hallum restated a “buy” rating and set a $41.00 target price on shares of Indivior in a report on Friday, October 31st. Morgan Stanley reiterated an “overweight” rating and issued a $36.00 price target on shares of Indivior in a report on Wednesday, December 3rd. Finally, Northland Securities set a $50.00 price objective on shares of Indivior in a research report on Tuesday, January 20th. Five analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, Indivior currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.33.

Insider Buying and Selling

In related news, Director Daniel A. Ninivaggi bought 775 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were acquired at an average price of $35.39 per share, with a total value of $27,427.25. Following the completion of the transaction, the director owned 16,923 shares in the company, valued at $598,904.97. The trade was a 4.80% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Mark Stejbach bought 775 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were bought at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the acquisition, the director directly owned 16,847 shares of the company’s stock, valued at $596,215.33. This represents a 4.82% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 4,871 shares of company stock worth $172,385 over the last three months.

Institutional Trading of Indivior

Several institutional investors and hedge funds have recently bought and sold shares of the business. Polymer Capital Management US LLC bought a new stake in shares of Indivior during the third quarter worth approximately $238,000. Rafferty Asset Management LLC acquired a new stake in Indivior during the 4th quarter worth approximately $237,000. Cerity Partners LLC acquired a new stake in Indivior during the 4th quarter worth approximately $229,000. Abel Hall LLC bought a new stake in Indivior in the 4th quarter valued at $226,000. Finally, CIBC Private Wealth Group LLC acquired a new position in Indivior in the 4th quarter valued at $216,000. Institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.